Literature DB >> 15150675

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Lisa Bodei1, Marta Cremonesi, Chiara Grana, Paola Rocca, Mirco Bartolomei, Marco Chinol, Giovanni Paganelli.   

Abstract

Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue (90)Y-[DOTA](0)-Tyr(3)-octreotide [(90)Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15150675     DOI： 10.1007/s00259-004-1571-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  38 in total

1.  New advances in peptide receptor radionuclide therapy.

Authors:  Marion de Jong; Eric Krenning
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

2.  Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

Authors:  M de Jong; W A Breeman; B F Bernard; W H Bakker; T J Visser; P P Kooij; A van Gameren; E P Krenning
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

3.  End-stage renal disease after treatment with 90Y-DOTATOC.

Authors:  M Cybulla; S M Weiner; A Otte
Journal:  Eur J Nucl Med       Date:  2001-10

4.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors:  Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

Review 5.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.

Authors:  M di Bartolomeo; E Bajetta; R Buzzoni; L Mariani; C Carnaghi; L Somma; N Zilembo; A di Leo
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

Review 8.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236

9.  Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.

Authors:  M Bontenbal; J A Foekens; S W Lamberts; F H de Jong; W L van Putten; H J Braun; J T Burghouts; G H van der Linden; J G Klijn
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.

Authors:  K J O'Byrne; N Dobbs; D J Propper; J P Braybrooke; M I Koukourakis; K Mitchell; J Woodhull; D C Talbot; A V Schally; A L Harris
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640
View more
  62 in total

1.  From the magic bullet to an effective therapy: the peptide experience.

Authors:  Luigi Mansi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

2.  Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.

Authors:  Sangeeta Ray Banerjee; Catherine A Foss; Mrudula Pullambhatla; Yuchuan Wang; Senthamizhchelvan Srinivasan; Robert F Hobbs; Kwamena E Baidoo; Martin W Brechbiel; Sridhar Nimmagadda; Ronnie C Mease; George Sgouros; Martin G Pomper
Journal:  J Nucl Med       Date:  2015-02-26       Impact factor: 10.057

Review 3.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

Review 4.  Time to demand dosimetry for molecular radiotherapy?

Authors:  D R McGowan; M J Guy
Journal:  Br J Radiol       Date:  2015-01-09       Impact factor: 3.039

5.  A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68Ga-DOTATOC in healthy volunteers.

Authors:  Shadi A Esfahani; Stephanie Salcedo; Pedram Heidari; Onofrio A Catalano; Rachel Pauplis; Jacob Hesterman; James F Kronauge; Umar Mahmood
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-04-15

6.  Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.

Authors:  Constantin Lapa; Rudolf A Werner; Christina Bluemel; Katharina Lückerath; Andreas Schirbel; Alexander Strate; Andreas K Buck; Ken Herrmann
Journal:  EJNMMI Res       Date:  2014-08-23       Impact factor: 3.138

7.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

Review 8.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

Review 9.  Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Natalie Prinzi; Martina Imbimbo; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Marco Maccauro; Roberto Buzzoni; Ettore Seregni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-07-27

10.  Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.

Authors:  Marleen Melis; Magda Bijster; Monique de Visser; Mark W Konijnenberg; Jan de Swart; Edgar J Rolleman; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.